Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

This study has suspended participant recruitment.
(Clinical hold enacted due to increased risk of blood clot.)
Information provided by (Responsible Party):
Peter S. Hammerman, Dana-Farber Cancer Institute Identifier:
First received: September 26, 2012
Last updated: October 22, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)